Please Wait
Applying Filters...
menu
    • menu
    FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Jan 2026 highlights: Astra, CSPC sign up to US$ 18.5 bn obesity deal; Wegovy’s pill version debuts in US

    Stock Recap
    #PipelineProspector

    Menu

    Pasireotide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Labeler NDC Package Code Non Proprietary Name Start Marketing Date End Marketing Date Category Code Dosage Form (Strength)
    27/02/2026 Synergy Health AST, LLC 71161-130 pasireotide 2018-06-29 2026-12-31 DRUG FOR FURTHER PROCESSING INJECTION, POWDER, FOR SUSPENSION (15mg/mL)
    27/02/2026 Synergy Health AST, LLC 71161-129 pasireotide 2014-12-15 2026-12-31 DRUG FOR FURTHER PROCESSING INJECTION, POWDER, FOR SUSPENSION (10mg/mL)
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.